Pancreatic Cancer Research

ResearcherYanbian UniversityActive in the last 2 years

Anna Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8180-6214; OpenAlex author ID A5031198404, A5072402605. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 4

  1. Taraxasterol regulates p53 transcriptional activity to inhibit pancreatic cancer by inducing MDM2 ubiquitination degradation. Co-author DOI 10.1016/j.phymed.2024.156298↗
  2. The CPT1A/Snail axis promotes pancreatic adenocarcinoma progression and metastasis by activating the glycolytic pathway. Co-author DOI 10.1016/j.isci.2023.107869↗
  3. [Clinicopathological significance of SMC4 expression in pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112151-20230215-00133↗
  4. HSDL2 Acts as a Promoter in Pancreatic Cancer by Regulating Cell Proliferation and Lipid Metabolism. Co-author DOI 10.2147/ott.s287722↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhenhua Lin · 2 shared papers, 2021–2023 · strength 0.36
  2. Liyan Chen · 1 shared paper, 2025 · strength 0.28
  3. Zhenhua Lin · 1 shared paper, 2025 · strength 0.28
  4. Z H Lin · 1 shared paper, 2023 · strength 0.22
  5. Shipeng Yang · 1 shared paper, 2023 · strength 0.20
  6. Yang Yang · 1 shared paper, 2023 · strength 0.20
  7. Wan-Shan Yang · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.